{
    "2021-01-27": [
        [
            {
                "time": "2021-01-27",
                "original_text": "万盛股份连发股权转让与定增方案 将易主“复星系”郭广昌 资产异常",
                "features": {
                    "keywords": [
                        "万盛股份",
                        "股权转让",
                        "定增方案",
                        "复星系",
                        "郭广昌"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "化工"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "格隆汇港股聚焦(01.27)︱建业新生活年度纯利预增逾八成；药明生物年度净利预增超65%",
                "features": {
                    "keywords": [
                        "建业新生活",
                        "药明生物",
                        "纯利预增",
                        "净利预增"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "房地产服务",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "智通港股公告精选|(1.27) 药明生物预期2020年度股东应占利润同比增65%以上",
                "features": {
                    "keywords": [
                        "药明生物",
                        "股东应占利润",
                        "同比增65%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "复星首批新冠疫苗2月抵港 争取尽快在内地应用",
                "features": {
                    "keywords": [
                        "复星",
                        "新冠疫苗",
                        "抵港",
                        "内地应用"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "复星医药(02196)拟发行2021年公司债券(第一期)",
                "features": {
                    "keywords": [
                        "复星医药",
                        "公司债券",
                        "发行"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "上海复星高科技(集团)增持复星医药(02196)265万股，每股作价38.23港元",
                "features": {
                    "keywords": [
                        "上海复星高科技",
                        "复星医药",
                        "增持",
                        "每股作价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "复星医药：目前公司已启动2020年相关减值测试工作",
                "features": {
                    "keywords": [
                        "复星医药",
                        "减值测试"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}